Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

NCT04446117 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

575

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Prostate Cancer
Prostate Adenocarcinoma

Interventions

DRUG: Cabozantinib
DRUG: Atezolizumab
DRUG: Abiraterone Acetate
DRUG: Enzalutamide
DRUG: Prednisone

Sponsor

Exelixis

Collaborators

[object Object]
[object Object]